Fact CheckerSign in

NCT06625788Not yet recruiting

Clinical and Endoscopic Characterization of Patients With Multiple Colorectal Adenomas: A Multicenter Study in Spain (ESPAPOLYP Study)

CARACTERIZACIÓN CLÍNICA Y ENDOSCÓPICA DE PACIENTES CON MÚLTIPLES ADENOMAS COLORRECTALES: ESPAPOLIP

Source: ClinicalTrials.gov · Last updated 3 Oct 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The aim is to clinically, endoscopically, and molecularly characterize patients with multiple colorectal adenomas, establish the indication for genetic testing to rule out hereditary syndromes and identify the genes to be included, and improve endoscopic screening recommendations for these patients and their relatives.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
200 (estimated)
First submitted
1 Oct 2024
Start date
1 Oct 2024
Primary completion date
1 Oct 2026
Lead sponsor
Asociación Española de Gastroenterología
NCT number
NCT06625788

What you commit to

  • Study type: Observational
  • Planned participants: 200
  • From 1 Oct 2024 to the primary completion date, 1 Oct 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Inflammatory bowel disease

Other

  • Inhereted condictions

Who the study is looking for

  • 10 or more adenomas
  • \>18 years

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Asociacion Española de Gastroenterologua
Coordinator of this site? Confirm its status
MadridSpainUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.